The global alopecia treatment (hair loss) market is witnessing significant growth due to the rising prevalence of hair loss conditions, increasing awareness about available treatment options, and advancements in technology. Alopecia can affect individuals of all ages and genders, leading to emotional distress and a negative impact on self-esteem. The market offers various treatment approaches, including medications, surgical procedures, and hair transplant techniques. With a focus on improving hair growth and restoring confidence, the alopecia treatment market continues to evolve, providing solutions to individuals experiencing hair loss.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-alopecia-treatment-hair-loss-market
Data Bridge Market Research analyses that the Alopecia Treatment (Hair Loss) Market is valued and will reach USD 6,266.73 million by 2030, growing at a CAGR of 7.12% during the forecast period of 2023 to 2030. The rising prevalence of hair loss conditions, such as androgenetic alopecia, alopecia areata, and traction alopecia, is a major driver for the global alopecia treatment market. The growing number of individuals affected by hair loss fuels the demand for effective treatment options.
Key Findings of the Study
Rise in the geriatric population is expected to drive the market's growth rate
The rise in the geriatric population globally has led to an increased demand for alopecia treatment. As individuals age, they often experience age-related hair loss, which can impact their appearance and self-esteem. Many older individuals are motivated to seek effective treatment options to address this concern and maintain a more youthful appearance. This growing desire to combat age-related hair loss has driven the demand for alopecia treatment among the elderly population.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia, Non‒Cicatricial Alopecia, Traction Alopecia, Ciatricial Alopecia, Alopecia Totalis, Alopecia Universalis, Others), Treatment (Localized Therapies, Medical Devices, Systemic Therapies, Herbal Treatment, Hair Transplant Services, Low Level Laser Therapy), Drug Type (Topical Agents, Oral Drugs, Injections, Corticosteroids, Immunosuppressants, Minoxidil, Finasteride, Others), Gender (Male, Female), Age Group (Below 18 Years, 18-34 Years, 35-49 Years, Above 50 Years), Form (Topical, Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Drug Stores, Dermatology Clinics, Retail Pharmacy, Online Pharmacy, Others), End-Users (Hospitals, Dermatologic, and Trichology Clinics, Aesthetic Clinics, Specialty Clinics, Homecare, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Cipla Inc. (U.S.), Endo International plc (Ireland), Zydus Group (India), Abbott (U.S.), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd. (India), Perrigo Company plc (Ireland), Curallux, LLC. (U.S.), DR. KURT WOLFF GMBH & CO. KG (Germany), WOCKHARDT (India), Sun Pharmaceutical Industries Ltd.(India), Concert Pharmaceuticals. (U.S.), Cipla Inc. (India), DAIICHI SANKYO COMPANY, LIMITED. (Japan) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-users, and distribution channel.
- On the basis of disease type, the global alopecia treatment (hair loss) market is segmented into non‒cicatricial alopecia, traction alopecia, ciatricial alopecia, and others. non‒cicatricle alopecia segment is expected to dominate the market with 54.80% market share in the forecast period of 2023-2030 due to its the most common type of alopecia which affects the major population
In 2023, non‒the cicatricle alopecia segment is expected to dominate the disease type segment of the market
In 2023, non‒cicatricle alopecia segment is expected to dominate the market owing to it being the most common type of alopecia which affects the major populace. Androgenetic alopecia is an everyday source of hair loss in both men and women. This form of hair loss affects a predictable 50 million men and 30 million women with a 54.80% market share in the forecast period of 2023-2030
- On the basis of treatment, the global alopecia treatment (hair loss) market is segmented into localized therapies, medical devices, systemic therapies, and herbal treatment. The localized therapies segment is expected to dominate the alopecia treatment (hair loss) market with a CAGR of 6.6% in the forecast period of 2023-2030 due to localized therapies are the first-line treatment therapies and if new hair growth occurs from corticosteroid injections as it is usually visible within four weeks. These types of therapies are considered easy to use and have minimal side effects.
- On the basis of gender, the global alopecia treatment (hair loss) market is segmented into male and female. The male segment is expected to dominate the alopecia treatment (hair loss) market with a CAGR of 6.6% in the forecast period of 2023-2030 because according to the U.S. National Library of Medicine and the American Hair Loss Association, nearly 50% of men experience some grade of hair fall by 50 years of age. Androgen is a leading cause of androgenetic alopecia in men.
- On the basis of form, the global alopecia treatment (hair loss) market is segmented into topical, oral, and parenteral. The topical segment is expected to dominate the alopecia treatment (hair loss) market with a 49.46% market share in the forecast period of 2023-2030 due to the low risk of systemic adverse events and drug interactions.
In 2023, the topical segment is expected to dominate the form segment of the alopecia treatment (hair loss) market
In 2023, the topical segment is expected to dominate the alopecia treatment (hair loss) market owing to the low risk of systemic adverse events and drug interactions and approximately 40 to 50% of patients treated with topical formulations will regrow scalp hairs after about six months of treatment with 49.46% market share in the forecast period of 2023-2030.
- On the basis of end-users, the global alopecia treatment (hair loss) market is segmented into dermatology centers, hospitals, and home healthcare. The dermatology centers segment is expected to dominate the alopecia treatment (hair loss) market with an of 6.2% in the forecast period of 2023-2030 due to dermatology centers having specialized professionals and increasing prevalence of alopecia and restoration surgeries coupled with the widespread applications of prescription medicines.
- On the basis of distribution channel, the global alopecia treatment (hair loss) market is segmented into pharmacies, retail sales, and direct tender. The pharmacies segment is expected to dominate the alopecia treatment (hair loss) market with a CAGR of 6.3% in the forecast period of 2023-2030 due to the treatment of alopecia, some drugs are OTC and some are prescription-based drugs. Pharmacies are the first place for the purchase of drugs according to the need of patients.
Major Players
Data Bridge Market Research recognizes the following companies as the major alopecia treatment (hair loss) market players in alopecia treatment (hair loss) markets are Johnson & Johnson Private Limited (U.S.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Cipla Inc. (U.S.), Endo International plc (Ireland), Zydus Group (India), Abbott (U.S.), Aurobindo Pharma (India)
Market Development
- In 2021, Pfizer announced the results of the productive phase 2b/3 alopecia ritlecitinib trial. A new class of covalent kinase inhibitors, which includes ritlecitinib, have the Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family as their initial targets.
- In 2020, Eli Lilly and Company received breakthrough designation from FDA for baricitinib indicated for alopecia areata treatment. This designation has allowed the company to accelerate the product developmental procedure and also allowed it to earn incentives.
- In 2019, WON TECH Co., Ltd. received FDA approval for HairBoom Air. This device utilizes LLLT for alopecia treatment and has been proven comfortable to wear and easy to use. This has been reported that this device provides effective results just by using it for 18 minutes once a day. This approval has helped enhance the company’s product portfolio.
Regional Analysis
Geographically, the countries covered in the alopecia treatment (hair loss) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the alopecia treatment (hair loss) market during the forecast period 2023-2030
North America dominates the market and will continue to flourish its trend of dominance during the forecast period. The common form of alopecia and the effects that people with alopecia experience have driven the regional market. The primary driver of the regional market's growth, however, is a market that is expanding and attracting new competitors.
Asia-Pacific is estimated to be the fastest-growing region in the alopecia treatment (hair loss) market in the forecast period 2023-2030
Asia-Pacific will undergo the highest growth rate during the forecast period owing to the rising use of hair care treatments for alopecia and an increase in its prevalence. Moreover, improving the healthcare regulatory scenario in developing countries is expected to attract international players to invest and capitalize on the available market opportunities
For more detailed information about the alopecia treatment (hair loss) market report, click here – https://www.databridgemarketresearch.com/reports/global-alopecia-treatment-hair-loss-market
